TABLE 3.
Clinical outcome of umbilical cord-mesenchymal stem cells (UC-MSC) treatment for stroke.
| No. | Route | Dose | Cell type | Motor improvement | Assessment modality | Major outcome |
| P1 | Intravenous | 1–2 × 106/kg | Allogenic UC-MSCs | Major | NIHSS, RMA, BBS, CAHAI-13 | Improvement in hand and upper extremity functions |
| P2 | Intravenous | 1–2 × 106/kg | Allogenic UC-MSCs | Major | NIHSS | Improvement in upper and lower extremity functions |
| P3 | Intravenous | 1–2 × 106/kg | Allogenic UC-MSCs | Major | NIHSS, RMA, BSS, CAHAI-13 | Improvement upper extremity functions |
| P4 | Intravenous | 1–2 × 106/kg | Allogenic UC-MSCs | Major | NIHSS | Improvement in fine motor functions |
| P5 | Intravenous | 1–2 × 106/kg | Allogenic UC-MSCs | Major | NIHSS | Improvement in all extremity muscle strength |